Medical News

RSS

Markers that cause primary liver cancer identified

Hepatocellular carcinoma (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year.

21 Oct 2009

Applied Biosystems announces the commercial availability of SOLiD 3 Plus System

Applied Biosystems, part of Life Technologies Corporation today announced the commercial availability of the SOLiD™ 3 Plus System, an enhanced next-generation genomic analysis platform designed to allow researchers to move one step closer to performing mainstream sequencing of personal genomes for clinical research and personalized medicine.

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Update from SemBioSys Genetics regarding Botaneco Specialty Ingredients

SemBioSys Genetics Inc. today announced that Advitech Inc. ("Advitech") has entered into a definitive agreement to acquire all of the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and Avrio Ventures Limited Partnership ("Avrio").

21 Oct 2009

St. Jude Medical announces fiscal 2009 third-quarter results

St. Jude Medical, Inc. today reported sales and net earnings for the third quarter ended October 3, 2009.

21 Oct 2009

PHNS to obtain federal electronic health record stimulus funds

PHNS Inc. announced that it has been engaged by NorthBay Healthcare (NorthBay), Fairfield, California, to assess its readiness to obtain federal electronic health record stimulus funds. The American Recovery and Reinvestment Act of 2009 (ARRA) provides approximately $34 billion of federal funds for improved electronic health records and connectivity to improve patient care and quality.

21 Oct 2009

Study on childhood risk factors for the development of future substance use disorders

There is ample evidence for the genetic influence of alcohol dependence, and ongoing studies are actively looking for specific genes that may confer this increased susceptibility. In addition, while it is well-known that individual risk is increased with the number of relatives with alcohol dependence, scientists have not been in a position to identify who among these individuals might have greater or lesser risk.

21 Oct 2009

Shire to file a Biologics License Application for REPLAGAL with the FDA

Shire plc, the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year.

21 Oct 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

New health information website launched in the United Kingdom by WebMD Health

WebMD Health Corp., the leading source of health information, and Boots UK, the UK's leading pharmacy-led health and beauty retailer, today announced the launch of a new health information website in the United Kingdom. The strategic partnership with Boots UK expands WebMD's presence internationally and will engage British consumers on the health and wellness issues that are most relevant to them.

21 Oct 2009

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.

21 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

Professor secures grant for further research on immunotherapy strategies

Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment.

21 Oct 2009

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled.

21 Oct 2009

Study suggests superiority of CT scans over X-Rays in detecting abnormalities in patients with the H1N1 virus

Computed tomography (CT) scans are better than standard radiography (X-rays) in showing the extent of disease in patients with the H1N1 virus, according to a study to be published online Oct. 21, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.

21 Oct 2009

Maternal smoking may increase the level of distress of newborns, says study

A new research study being published in the October 15th issue of Biological Psychiatry suggests that maternal smoking may increase the level of distress of newborns.

21 Oct 2009

First Edition: October 21, 2009

As Senate Democrats wrestle with a doctor payment bill separate from sweeping health care reform proposals, the public plan, public opinion and health care costs continue to be a Capitol Hill focus.

21 Oct 2009

Study reveals a dramatic increase in TTB cases

Babesiosis is a potentially dangerous parasitic disease transmitted by ticks and is common in the Northeast and the upper Midwest. Babesia lives inside of red blood cells, meaning it can also be transmitted through a blood transfusion from an infected but otherwise asymptomatic blood donor.

21 Oct 2009

Life science tool companies must consider multiple factors to develop strategies for future

Companies involved in the life science tools market must consider a multitude of technologies, economic drivers and societal trends in developing strategies for the future.

21 Oct 2009

Health care experts and policy makers assemble to address current health care reform

The New Republic will host health care experts and policy makers for the decisive conference on the current health care reform debate. Jonathan Cohn, senior editor of The New Republic, health care expert and author will moderate the forum.

21 Oct 2009